

**REGISTERED NUMBER: 03165707 (England and Wales)**

Unaudited Financial Statements for the Year Ended 31 December 2016

for

WORPHMED World Orphan Medicines Limited

Contents of the Financial Statements  
for the Year Ended 31 December 2016

	Page
Company Information	1
Balance Sheet	2
Notes to the Financial Statements	3

<b>DIRECTOR:</b>	Mrs M A Seville
<b>SECRETARY:</b>	Inter.Gala Corporate Secretaries Ltd
<b>REGISTERED OFFICE:</b>	1st Floor Victory House 99-101 Regent Street London W1B 4EZ
<b>REGISTERED NUMBER:</b>	03165707 (England and Wales)
<b>ACCOUNTANTS:</b>	Lextray (UK) Ltd 1st Floor, Victory House 99 - 101 Regent Street London W1B 4EZ

Balance Sheet  
31 December 2016

	Notes	31.12.16 \$	31.12.15 \$
<b>CURRENT ASSETS</b>			
Debtors	3	10,780	-
Cash at bank		<u>52,639</u>	<u>-</u>
		63,419	-
<b>CREDITORS</b>			
Amounts falling due within one year	4	<u>454,642</u>	<u>280,765</u>
<b>NET CURRENT LIABILITIES</b>		<u>(391,223)</u>	<u>(280,765)</u>
<b>TOTAL ASSETS LESS CURRENT LIABILITIES</b>		<u>(391,223)</u>	<u>(280,765)</u>
<b>CAPITAL AND RESERVES</b>			
Called up share capital	5	1,640	1,640
Retained earnings		<u>(392,863)</u>	<u>(282,405)</u>
<b>SHAREHOLDERS' FUNDS</b>		<u>(391,223)</u>	<u>(280,765)</u>

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2016.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2016 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for:

- (a) ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions of Part 15 of the Companies Act 2006 relating to small companies.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director on 10 August 2017 and were signed by:

Mrs M A Seville - Director

Notes to the Financial Statements  
for the Year Ended 31 December 2016

1. **STATUTORY INFORMATION**

WORPHMED World Orphan Medicines Limited is a private company, limited by shares, registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. **ACCOUNTING POLICIES**

**Basis of preparing the financial statements**

These financial statements have been prepared in accordance with the provisions of Section 1A "Small Entities" of Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

The company has elected first time adoption of Financial Reporting Standard (FRS) 102 section 1A, with the effective date of transition being 01st January 2015. Information on the impact of transition to Financial Reporting Standard 102 is given in note 7.

Partner's profit share

Under a partnership agreement dated 12 March 1996, GLP Generic Licencing Programme Limited is entitled to receive a profit share amounting to 95% of all transactions administered on their behalf by Ranipharma Ltd. This is included in the cost of sales.

**Taxation**

Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

**Deferred tax**

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

3. **DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.16	31.12.15
	\$	\$
Prepayments and accrued income	<u>10,780</u>	<u>-</u>

Notes to the Financial Statements - continued  
for the Year Ended 31 December 2016

4. **CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR**

	31.12.16	31.12.15
	\$	\$
Trade creditors	50,077	50,000
Other creditors	404,565	229,565
Accruals and deferred income	-	1,200
	<u>454,642</u>	<u>280,765</u>

5. **CALLED UP SHARE CAPITAL**

Allotted, issued and fully paid:				
Number:	Class:	Nominal value:	31.12.16	31.12.15
			\$	\$
1,000	Ordinary	£1	<u>1,640</u>	<u>1,640</u>

6. **FIRST TIME ADOPTION OF FRS 102**

The policies adopted under the entity's previous accounting framework are not materially different from FRS 102 and have not impacted on equity or profit or loss.

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.